Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeomin scalp injection point comparison in chronic migraine
IRCT20200217046523N2Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of botulinum toxin type A in chronic migraine (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoint: Headache intensity. Started Sep 2020; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
chronic migraine
Beyond the preview
Go deeper on IRCT20200217046523N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200217046523N2.